Eduardo Laborda | Associate Director IO
Calibr at Scripps Research

Eduardo Laborda, Associate Director IO, Calibr at Scripps Research

Dr Laborda is the Associate Director of Immuno Oncology at Calibr, a division of Scripps Research, a non-profit research organization focused on addressing unmet needs through novel therapeutic approaches. He received a BS in Veterinary Medicine and a PhD in Biochemistry, Molecular Biology, and Biomedicine from Universidad Autonoma de Barcelona. His PhD focused on developing tumor selective Oncolytic Adenoviruses with enhanced potency for canine patients. This work lead to treating canine cancer patients under compassionate use with significant clinical responses, and informed on the human clinical trial run years later with a human version of a similar Oncolytic Adenovirus. After completing his PhD he joined Genelux Corporation for an Internship and later Calibr as a Postdoctoral Researcher where he has been part of the team developing the Universal “Switchable” CAR-T Cell Platform. The platform was partnered with AbbVie later on and is being investigated in the clinic for CD19 positive malignancies. Moreover, this team is  exploring the potential application of the switchable CAR-T cells for solid tumors.

Appearances:



Festival of Biologics Day 2 @ 12:20

Universal “Switchable” CAR-T Cell Platform

  • Ability to control CAR-T cells is required to increase safety, efficacy, persistence and achieve broader applicability of Cell Therapies.  
  • The switchable CAR-T platform offers a controllable and universal cell therapy approach with:
  • titratable activity for reduced toxicity
  • capable of being turned ON and OFF modelling the physiological cycle of T cell stimulation to enhance memory cell formation and increased persistence
  • easy retargeting against multiple antigens to maximize efficacy against heterogenous tumors and decrease antigen negative relapses.
  • We have validated the switchable CAR-T platform against multiple liquid and solid tumor models, on single and dual antigen targeting setting, and are currently evaluating it on the clinic against CD19 positive B cell malignancies.
  • last published: 31/Jan/23 09:55 GMT
    last published: 31/Jan/23 09:55 GMT

    back to speakers